Vice President & Head of Neuroscience Portfolio Strategy & Alliances

Job description

At Bristol Myers Squibb, our employees often ask, “Who are you working for?”—a question that fuels collaboration, accountability, and urgency in our work. Our purpose-driven culture inspires us to discover, develop, and deliver innovative medicines to prevail over serious diseases. We offer uniquely interesting and meaningful work, opportunities for growth, and a supportive environment that values inclusion, wellbeing, flexibility, and comprehensive benefits. This is work that transforms the lives of patients, and the careers of those who do it. Position: Vice President & Head of Neuroscience Portfolio Strategy & AlliancesLocation: Princeton Pike, NJReporting to: Senior Vice President, Head of Global Medical Neuroscience Working with Us Challenging. Meaningful. Life-changing. Those aren’t words that are usually associated with a job. But working at Bristol Myers Squibb is anything but usual. Here, uniquely interesting work happens every day, in every department. From optimizing a production line to the latest breakthroughs in cell therapy, this is work that transforms the lives of patients, and the careers of those who do it. You’ll get the chance to grow and thrive through opportunities uncommon in scale and scope, alongside high-achieving teams rich in diversity. Take your career farther than you thought possible. Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives. Read more: careers.bms.com/working-with-us Position Summary Bristol Myers Squibb is seeking an enterprise-minded leader to serve as Vice President & Head of Neuroscience Portfolio Strategy & Alliances. This leader will be responsible for shaping and integrating the overarching Neuroscience portfolio strategy across neuropsychiatry and neurology, including dementia and other neurodegenerative diseases. The role will translate individual disease-area and asset strategies into clear portfolio-level choices regarding asset and indication prioritization, investment, resource allocation, sequencing, external partnerships, and enterprise positioning. The leader will also lead the strategic orchestration of BMS's overarching Neuroscience and Brain Health external narrative, enterprise neuroscience congress strategy, strategic alliances, SPARC, and relevant public-private partnerships. Working across Medical, Research and Development, Commercial, Corporate Affairs, Investor Relations, Business Development, Alliance Management, and other enterprise functions, this leader will ensure that BMS presents a coherent neuroscience ambition and focuses its resources and external engagement on the opportunities with the greatest potential impact for patients. This is a highly visible, matrixed leadership role requiring scientific credibility, portfolio judgment, business acumen, and the ability to align senior leaders around consequential choices. Key Responsibilities Integrated Neuroscience Portfolio Strategy and Prioritization Lead the development and ongoing evolution of the integrated Neuroscience portfolio strategy across neuropsychiatry, dementia, and other neurodegenerative diseases, grounded in scientific opportunity, unmet patient need, clinical practice, and the external treatment landscape. Integrate disease-area and asset strategies into a cohesive Neuroscience portfolio ambition, identifying strategic priorities, interdependencies, portfolio gaps, evidence needs, and opportunities for differentiation. Bring a distinct Medical and scientific perspective to cross-portfolio assessments, including the patient journey, evolving standards of care, clinical meaningfulness, evidence requirements, external stakeholder needs, and the feasibility of changing medical practice. Lead cross-portfolio assessments and scenario planning to inform choices among assets, indications, evidence-generation opportunities, external collaborations, and investments. Develop transparent prioritization frameworks that incorporate unmet patient need, strength of scientific rationale, clinical potential, probability of success, competitive differentiation, evidence requirements, feasibility, strategic fit, and enterprise value. Partner with Disease Area Heads, Research, Development, Commercial, Finance, and enterprise portfolio teams to formulate recommendations regarding asset and indication prioritization, resource allocation, portfolio sequencing, acceleration, expansion, partnering, or deprioritization. Ensure that portfolio recommendations reflect both internal asset potential and the external realities of clinical practice, patient needs, scientific advancement, and the evolving competitive environment. Reassess portfolio priorities as scientific evidence, development milestones, clinical practice, competitive conditions, external opportunities, and enterprise priorities evolve. Provide the Neuroscience Leadership Team and relevant governance bodies with clear, decision-ready recommendations, including the scientific and medical rationale, patient implications, strategic trade-offs, risks, and resource requirements. Neuroscience and Brain Health Scientific Narrative and External Medical Strategy Lead the development of the overarching Neuroscience and Brain Health scientific narrative, connecting BMS's disease areas, assets, scientific platforms, evidence, partnerships, and patient priorities into a coherent expression of the company's scientific ambition. Ensure that the narrative is scientifically rigorous, clinically relevant, patient-centered, and appropriately grounded in the maturity and evidence supporting the portfolio. Define the core scientific and medical themes that should guide BMS Neuroscience engagement with healthcare professionals, researchers, scientific societies, patient and advocacy communities, academic institutions, consortia, and other health-system stakeholders. Partner with Disease Area Heads and asset teams to ensure that individual disease and asset narratives contribute to—and remain consistent with—the broader Neuroscience and Brain Health scientific strategy. Identify scientific, evidence, and external-understanding gaps that could limit differentiation of the Neuroscience portfolio and work with the appropriate teams to address them. Translate the scientific narrative into clear strategic guidance for scientific exchange, evidence generation, publications, medical education, congress engagement, partnerships, and other external Medical activities. Partner with Corporate Affairs to ensure that the scientific and medical foundations of the portfolio are accurately reflected in the broader enterprise Neuroscience narrative and external communications. Provide scientific and medical context to Investor Relations, Commercial, Government Affairs, and other functions while respecting their ownership of investor communications, brand positioning, policy engagement, communications channels, and functional execution. Ensure that insights generated through external scientific and patient engagement inform the ongoing evolution of the Neuroscience portfolio strategy and scientific narrative. Enterprise Neuroscience Congress Strategy and Oversight Own the overarching enterprise congress strategy for Neuroscience across priority global, US, and regional scientific meetings. Establish the Neuroscience congress portfolio, including congress tiering, investment priorities, enterprise objectives, target audiences, expected outcomes, and leadership engagement. Convene and align Medical, Development, Commercial, Corporate Affairs, Investor Relations, Congress Excellence, and other relevant teams around an integrated strategy for major neuroscience congresses. Ensure that scientific disclosures, medical education, external engagement, executive participation, media activity